{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:11Z","timestamp":1786980491825,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK plc","doi-asserted-by":"crossref","award":["Industry PhD Scholarship"],"award-info":[{"award-number":["Industry PhD Scholarship"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001786","name":"The University of Adelaide","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001786","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>In this prospective cohort study, we provide several prognostic models to predict functional status as measured by the modified Health Assessment Questionnaire (mHAQ). The early adoption of the treat-to-target strategy in this cohort offered a unique opportunity to identify predictive factors using longitudinal data across 20\u00a0years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort of 397 patients with early RA was used to develop statistical models to predict mHAQ score measured at baseline, 12\u00a0months, and 18\u00a0months post diagnosis, as well as serially measured mHAQ. Demographic data, clinical measures, autoantibodies, medication use, comorbid conditions, and baseline mHAQ were considered as predictors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The discriminative performance of models was comparable to previous work, with an area under the receiver operator curve ranging from 0.64 to 0.88. The most consistent predictive variable was baseline mHAQ. Patient-reported outcomes including early morning stiffness, tender joint count (TJC), fatigue, pain, and patient global assessment were positively predictive of a higher mHAQ at baseline and longitudinally, as was the physician global assessment and C-reactive protein. When considering future function, a higher TJC predicted persistent disability while a higher swollen joint count predicted functional improvements with treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In our study of mHAQ prediction in RA patients receiving treat-to-target therapy, patient-reported outcomes were most consistently predictive of function. Patients with high disease activity due predominantly to tenderness scores rather than swelling may benefit from less aggressive treatment escalation and an emphasis on non-pharmacological therapies, allowing for a more personalized approach to treatment.\n                      <jats:table-wrap>\n                        <jats:table>\n                          <jats:tbody>\n                            <jats:tr>\n                              <jats:td colspan=\"2\">\n                                <jats:bold>Key Points<\/jats:bold>\n                                <jats:italic>\u2022\u00a0Long-term use of the treat-to-target strategy in this patient cohort offers a unique opportunity to develop prognostic models for functional outcomes using extensive longitudinal data.<\/jats:italic>\n                                <jats:italic>\u2022\u00a0Patient reported outcomes were more consistent predictors of function than traditional prognostic markers.<\/jats:italic>\n                                <jats:italic>\u2022\u00a0Tender joint count and swollen joint count had discordant relationships with future function, adding weight to the possibility that disease activity may better guide treatment when the components are considered separately.<\/jats:italic>\n                              <\/jats:td>\n                            <\/jats:tr>\n                          <\/jats:tbody>\n                        <\/jats:table>\n                      <\/jats:table-wrap>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-024-06946-z","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T07:03:24Z","timestamp":1711523004000},"page":"1503-1512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic modeling in early rheumatoid arthritis: reconsidering the predictive role of disease activity scores"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8676-0822","authenticated-orcid":false,"given":"Alix","family":"Bird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Oakden-Rayner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shonket","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Proudman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyle J.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"key":"6946_CR1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJM199005033221805","volume":"322","author":"ED Harris Jr","year":"1990","unstructured":"Harris ED Jr (1990) Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 322:1277\u20131289","journal-title":"N Engl J Med"},{"key":"6946_CR2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JWJ et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631\u2013637","journal-title":"Ann Rheum Dis"},{"key":"6946_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/art.10117","volume":"46","author":"H Visser","year":"2002","unstructured":"Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW (2002) How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46:357\u2013365","journal-title":"Arthritis Rheum"},{"key":"6946_CR4","first-page":"1503","volume":"33","author":"N Bansback","year":"2006","unstructured":"Bansback N, Young A, Brennan A, Dixey J (2006) A prognostic model for functional outcome in early rheumatoid arthritis. J Rheumatol 33:1503\u20131510","journal-title":"J Rheumatol"},{"key":"6946_CR5","first-page":"S20","volume":"21","author":"DL Scott","year":"2003","unstructured":"Scott DL, Smith C, Kingsley G (2003) Joint damage and disability in rheumatoid arthritis: an updated systematic review. Clin Exp Rheumatol 21:S20\u2013S27","journal-title":"Clin Exp Rheumatol"},{"key":"6946_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta22660","volume":"22","author":"R Archer","year":"2018","unstructured":"Archer R, Hock E, Hamilton J, Stevens J, Essat M, Poku E, Clowes M, Pandor A, Stevenson M (2018) Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews. Health Technol Assess 22:1\u2013294","journal-title":"Health Technol Assess"},{"key":"6946_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137\u2013145","journal-title":"Arthritis Rheum"},{"key":"6946_CR8","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/art.1780261107","volume":"26","author":"T Pincus","year":"1983","unstructured":"Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP (1983) Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 26:1346\u20131353","journal-title":"Arthritis Rheum"},{"key":"6946_CR9","doi-asserted-by":"crossref","unstructured":"Berrar D (2019) Cross-validation. https:\/\/www.researchgate.net\/profile\/Daniel-Berrar\/publication\/324701535_Cross-Validation\/links\/5cb4209c92851c8d22ec4349\/Cross-Validation.pdf. Accessed 13 Jun 2023","DOI":"10.1016\/B978-0-12-809633-8.20349-X"},{"key":"6946_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"6946_CR11","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569\u20132581","journal-title":"Arthritis Rheum"},{"key":"6946_CR12","volume-title":"Disease Modifying anti-rheumatic drugs (DMARD)","author":"O Benjamin","year":"2022","unstructured":"Benjamin O, Goyal A, Lappin SL (2022) Disease Modifying anti-rheumatic drugs (DMARD). StatPearls Publishing"},{"key":"6946_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.semarthrit.2007.02.001","volume":"37","author":"SM Proudman","year":"2007","unstructured":"Proudman SM, Keen HI, Stamp LK et al (2007) Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin Arthritis Rheum 37:99\u2013111","journal-title":"Semin Arthritis Rheum"},{"key":"6946_CR14","unstructured":"Pharmaceutical Benefits Scheme (PBS). In: Australian Government Department of Health and Aged Care. https:\/\/www.pbs.gov.au\/pbs\/industry\/listing\/elements\/pbac-meetings\/psd\/2009-12\/pbac-psd-bdmards-dec09. Accessed 24 Oct 2023"},{"key":"6946_CR15","unstructured":"of Statistics AB (2018) Socio-economic indexes for areas. SEIFA provides measures of socio-economic conditions by geographic area"},{"key":"6946_CR16","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2307\/2344614","volume":"135","author":"JA Nelder","year":"1972","unstructured":"Nelder JA, Wedderburn RWM (1972) Generalized linear models. J R Stat Soc Ser A 135:370\u2013384","journal-title":"J R Stat Soc Ser A"},{"key":"6946_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4419-0318-1_1","volume-title":"Mixed-effects models in S and S-PLUS","author":"JC Pinheiro","year":"2000","unstructured":"Pinheiro JC, Bates DM (2000) Linear mixed-effects models: basic concepts and examples. Mixed-effects models in S and S-Plus:3\u201356"},{"key":"6946_CR18","doi-asserted-by":"publisher","first-page":"g7594","DOI":"10.1136\/bmj.g7594","volume":"350","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KGM (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 350:g7594","journal-title":"BMJ"},{"key":"6946_CR19","volume-title":"Multiple imputation for nonresponse in surveys","author":"DB Rubin","year":"2004","unstructured":"Rubin DB (2004) Multiple imputation for nonresponse in surveys. John Wiley & Sons"},{"key":"6946_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1467-842X.2001.tb00294.x","volume":"25","author":"DA Bennett","year":"2001","unstructured":"Bennett DA (2001) How can I deal with missing data in my study? Aust N Z J Public Health 25:464\u2013469","journal-title":"Aust N Z J Public Health"},{"key":"6946_CR21","first-page":"557","volume":"20","author":"GA Wells","year":"1993","unstructured":"Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA (1993) Minimum important difference between patients with rheumatoid arthritis: the patient\u2019s perspective. J Rheumatol 20:557\u2013560","journal-title":"J Rheumatol"},{"key":"6946_CR22","unstructured":"Van Rossum G, Drake FL (1995) Python reference manual. http:\/\/www.cs.cmu.edu\/afs\/cs.cmu.edu\/project\/gwydion-1\/OldFiles\/OldFiles\/python\/Doc\/ref.ps. Accessed 21 Jul 2023"},{"key":"6946_CR23","doi-asserted-by":"publisher","unstructured":"Seabold S, Perktold J (2010) Statsmodels: econometric and statistical modeling with python. Proceedings of the 9th Python in Science Conference. https:\/\/doi.org\/10.25080\/majora-92bf1922-011","DOI":"10.25080\/majora-92bf1922-011"},{"key":"6946_CR24","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1609\/aaai.v34i04.5724","volume":"34","author":"S Bhatia","year":"2020","unstructured":"Bhatia S, Hooi B, Yoon M, Shin K, Faloutsos C (2020) Midas: microcluster-based detector of anomalies in edge streams. AAAI 34:3242\u20133249","journal-title":"AAAI"},{"key":"6946_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/ard.2003.014928","volume":"64","author":"SMM Verstappen","year":"2005","unstructured":"Verstappen SMM, van Albada-Kuipers GA, Bijlsma JWJ, Blaauw AAM, Schenk Y, Haanen HCM, Jacobs JWG, Utrecht Rheumatoid Arthritis Cohort Study Group (SRU) (2005) A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 64:38\u201343","journal-title":"Ann Rheum Dis"},{"key":"6946_CR26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.semarthrit.2018.03.004","volume":"48","author":"JM Gwinnutt","year":"2018","unstructured":"Gwinnutt JM, Sharp CA, Symmons DPM, Lunt M, Verstappen SMM (2018) Baseline patient reported outcomes are more consistent predictors of long-term functional disability than laboratory, imaging or joint count data in patients with early inflammatory arthritis: a systematic review. Semin Arthritis Rheum 48:384\u2013398","journal-title":"Semin Arthritis Rheum"},{"key":"6946_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-06869-9","author":"J O\u2019Brien","year":"2024","unstructured":"O\u2019Brien J, Park SH, Blachley T, Marchese M, Middaugh N, Wittstock K, Harrold LR (2024) Disparities in burden of disease in patients with rheumatoid arthritis across racial and ethnic groups. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-024-06869-9","journal-title":"Clin Rheumatol"},{"key":"6946_CR28","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1136\/ard.2009.118430","volume":"69","author":"H Radner","year":"2010","unstructured":"Radner H, Smolen JS, Aletaha D (2010) Impact of comorbidity on physical function in patients with rheumatoid arthritis. Ann Rheum Dis 69:536\u2013541","journal-title":"Ann Rheum Dis"},{"key":"6946_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383","journal-title":"J Chronic Dis"},{"key":"6946_CR30","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/acr.22456","volume":"67","author":"BR England","year":"2015","unstructured":"England BR, Sayles H, Mikuls TR, Johnson DS, Michaud K (2015) Validation of the rheumatic disease comorbidity index. Arthritis Care Res 67:865\u2013872","journal-title":"Arthritis Care Res"},{"key":"6946_CR31","doi-asserted-by":"publisher","first-page":"101423","DOI":"10.1016\/j.berh.2019.06.005","volume":"33","author":"SS Zhao","year":"2019","unstructured":"Zhao SS, Duffield SJ, Goodson NJ (2019) The prevalence and impact of comorbid fibromyalgia in inflammatory arthritis. Best Pract Res Clin Rheumatol 33:101423","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"6946_CR32","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1136\/annrheumdis-2015-207326","volume":"75","author":"JH Humphreys","year":"2016","unstructured":"Humphreys JH, Verheul MK, Barton A, MacGregor AJ, Lunt M, Toes RE, Symmons DP, Trouw LA, Verstappen SM (2016) Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 75:1139\u20131144","journal-title":"Ann Rheum Dis"},{"key":"6946_CR33","doi-asserted-by":"publisher","first-page":"e000738","DOI":"10.1136\/rmdopen-2018-000738","volume":"4","author":"JE Pope","year":"2018","unstructured":"Pope JE, Movahedi M, Rampakakis E, Cesta A, Sampalis JS, Keystone E, Thorne C, Bombardier C (2018) ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI). RMD Open 4:e000738","journal-title":"RMD Open"},{"key":"6946_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s41927-022-00299-3","volume":"6","author":"HL Pisaniello","year":"2022","unstructured":"Pisaniello HL, Whittle SL, Lester S, Menz F, Metcalf R, McWilliams L, Hill CL, Proudman S (2022) Using the derived 28-joint disease activity score patient-reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis. BMC Rheumatol 6:67","journal-title":"BMC Rheumatol"},{"key":"6946_CR35","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2522\/ptj.20070039","volume":"87","author":"A Christie","year":"2007","unstructured":"Christie A, Jamtvedt G, Dahm KT, Moe RH, Haavardsholm EA, Hagen KB (2007) Effectiveness of nonpharmacological and nonsurgical interventions for patients with rheumatoid arthritis: an overview of systematic reviews. Phys Ther 87:1697\u20131715","journal-title":"Phys Ther"},{"key":"6946_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41591-020-01192-7","volume":"27","author":"E Pierson","year":"2021","unstructured":"Pierson E, Cutler DM, Leskovec J, Mullainathan S, Obermeyer Z (2021) An algorithmic approach to reducing unexplained pain disparities in underserved populations. Nat Med 27:136\u2013140","journal-title":"Nat Med"},{"key":"6946_CR37","doi-asserted-by":"crossref","unstructured":"Harrell FE (2001) Regression modeling strategies. Springer Series in Statistics","DOI":"10.1007\/978-1-4757-3462-1"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06946-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-06946-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06946-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T01:15:10Z","timestamp":1713143710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-06946-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["6946"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-06946-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]},"assertion":[{"value":"21 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AB and LAS are funded by an unrestricted training grant from GSK plc, supervised by LOR and LJP. The other authors have disclosed no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}